Logo do repositório
 
Publicação

Bridging functional bionanomaterials and the clinic

2026Recensão Acesso aberto
Ver registo simples
dc.contributor.authorVrabie, Dana Mihaela
dc.contributor.authorYang, Fang
dc.contributor.authorWu, Aiguo
dc.contributor.authorLodeiro, Carlos
dc.contributor.authordel Pino, Pablo
dc.contributor.authorPelaz, Beatriz
dc.contributor.authorPanisoara, Georgeta
dc.contributor.authorSong, Young Min
dc.contributor.authorPopescu, Marius
dc.contributor.authorStanciu, Stefan G.
dc.contributor.authorMilitaru, Gheorghe
dc.contributor.institutionDQ - Departamento de Química
dc.contributor.institutionLAQV@REQUIMTE
dc.contributor.pblBioMed Central (BMC)
dc.date.accessioned2026-09-02T09:00:01Z
dc.date.available2026-09-02T09:00:01Z
dc.date.issued2026
dc.descriptionPublisher Copyright: © The Author(s) 2026.
dc.description.abstractFunctional bionanomaterials have enabled major advances in nanomedicine through their tunable physicochemical properties, multifunctionality, and ability to interact with biological systems in a controlled manner. Despite sustained progress in materials design and preclinical validation, the clinical translation of bionanomaterials remains limited, with only a small fraction achieving regulatory approval and routine clinical use. While technical performance, safety, manufacturing scalability, and regulatory complexity are widely recognized as key translational barriers, the role of strategic communication in shaping stakeholder understanding, trust, and adoption has received comparatively little attention. In this Perspective, we argue that strategic communication should be considered a core translational enabler for functional bionanomaterials rather than a downstream dissemination activity, as in current trends. We identify recurrent communication gaps between bionanomaterial developers and key stakeholders, including clinicians, patients, regulators, and investors, that contribute to misaligned expectations, heightened risk perception, and delayed clinical adoption. Drawing on examples from nanomedicine translation, we discuss how differences in language, decision-making frameworks, and perceived value across stakeholder groups, can impede progress even for technically mature platforms. Building on insights from translational medicine, behavioral science, and innovation studies, we propose a structured communication framework tailored to the specific challenges of functional bionanomaterials. This framework emphasizes early integration of communication planning, stakeholder-specific narrative framing, visual and digital tools to reduce cognitive complexity, and iterative feedback mechanisms. We further discuss practical approaches for evaluating communication impact using measurable indicators such as stakeholder awareness, trust, regulatory feedback, and clinical uptake. By reframing communication as a bidirectional and designable component of the translational pipeline, this Perspective aims to support more efficient pathways for bringing functional bionanomaterials from the laboratory to the clinic.en
dc.description.versionpublishersversion
dc.description.versionepub_ahead_of_print
dc.format.extent25
dc.format.extent4640894
dc.identifier.doi10.1186/s12951-026-04425-y
dc.identifier.issn1477-3155
dc.identifier.otherPURE: 169530390
dc.identifier.otherPURE UUID: c949e6b9-bf30-4e20-ba5a-80a8a2f662dc
dc.identifier.otherScopus: 105043627024
dc.identifier.otherPubMed: 42057181
dc.identifier.otherWOS: 001810605400001
dc.identifier.urihttp://hdl.handle.net/10362/205972
dc.identifier.urlhttps://www.scopus.com/pages/publications/105043627024
dc.identifier.urlhttps://www.webofscience.com/wos/woscc/full-record/WOS:001810605400001
dc.language.isoeng
dc.peerreviewedyes
dc.subjectBionanomaterials
dc.subjectClinical adoption
dc.subjectInnovation pathways
dc.subjectNanobiotechnology
dc.subjectNanomedicine translation
dc.subjectStakeholder engagement
dc.subjectStrategic communication
dc.subjectTranslational medicine
dc.subjectMedicine (miscellaneous)
dc.subjectBioengineering
dc.subjectApplied Microbiology and Biotechnology
dc.subjectMolecular Medicine
dc.subjectBiomedical Engineering
dc.subjectPharmaceutical Science
dc.titleBridging functional bionanomaterials and the clinicen
dc.title.subtitlestrategic communication as a translational enableren
dc.typereview
degois.publication.firstPage1
degois.publication.lastPage25
degois.publication.titleJournal of Nanobiotechnology
degois.publication.volume24
dspace.entity.typePublication
rcaap.rightsopenAccess

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Vrabie_et_al._2026_..pdf
Tamanho:
4.43 MB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

Home collection (FCT)